Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature).
We report here a case of recurrent venous and arterial thromboembolism, Trousseau's syndrome, in a cancer patient who developed heparin-induced thrombocytopenia. She was treated with lepirudin and after establishing the patient-specific half-life for subcutaneous lepirudin, she was successfully maintained on this therapy for more than eight months. To our knowledge this case represents the longest reported use of subcutaneous lepirudin.
Department of Medicine, University of Vermont, Burlington 05401, USA.
A C
AC
Andreescu
M
M
Cushman
J M
JM
Hammond
M E
ME
Wood
D000925:Anticoagulants / Q000008:administration & dosage; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006493:Heparin / Q000009:adverse effects; D006629:Hirudins / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D007279:Injections, Subcutaneous; D007700:Kinetics; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin